Jakubowitz Law
Business Minds. Legal Insight.

We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.

Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED Athira Pharma, Inc. (ATHA)

(1) the research conducted by Defendant Kawas, which formed the foundation for Athira’s product candidates and intellectual property, was tainted by Kawas’ scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.

If you incurred a loss on ATHA stocks purchased between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company’s registration statement issued in connection with the Company’s September 2020 initial public offering priced at $17.00 per share, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Western District of Washington, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until August 24, 2021 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Enter the following information for this class action case- the deadline is approaching.

See If you Qualify for Monetary Reward

Loss Submission Form

Submitting your information does not create an attorney-client relationship and you are giving us your express consent to contact you by email, text message, SMS, or call you by telephone.